articleThe LancetDec 5, 2012BRONZE OA

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

University of Oxford · Glasgow Caledonian University · +21 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,035
total citations
FWCI
55.14
Percentile
100%
References
23
Citations per year

Authors

38

Topics & keywords

Keywords
  • Medicine
  • Tamoxifen
  • Breast cancer
  • Internal medicine
  • Oncology
  • Cancer
  • Adverse effect
  • Gynecology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.